Latest Cannabis And Alternative Therapeutics News

Bioxyne Limited has reported a record-breaking first quarter for FY26, with revenues soaring 210% year-on-year, driven by strong demand in cannabis products and strategic European market advances.

Bioxyne Limited has reported a record quarterly revenue of A$14.1 million for Q1 FY26, driven by strong demand in Europe and Australia, alongside a strategic dual listing on the Frankfurt Stock Exchange.